DelveInsight’s, “Acute Respiratory Distress Syndrome Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in the Acute Respiratory Distress Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Acute Respiratory Distress Syndrome Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Acute Respiratory Distress Syndrome Pipeline landscape @ Acute Respiratory Distress Syndrome Pipeline Outlook Report
Acute Respiratory Distress Syndrome Overview
Acute Respiratory Distress Syndrome is a life-threatening acute lung injury commonly resulting from sepsis, trauma, and severe pulmonary infections that allows fluid to leak into the lungs. The signs and symptoms of Acute Respiratory Distress Syndrome vary in intensity, depending on its cause and severity, including severe shortness of breath, unusual rapid breathing, low blood pressure, confusion and extreme tiredness.
Recent Developmental Activities in the Acute Respiratory Distress Syndrome Treatment Landscape
For further information, refer to the detailed Acute Respiratory Distress Syndrome Drugs Launch, Acute Respiratory Distress Syndrome Developmental Activities, and Acute Respiratory Distress Syndrome News, click here for Acute Respiratory Distress Syndrome Ongoing Clinical Trial Analysis
Acute Respiratory Distress Syndrome Emerging Drugs Profile
BIO-11006 is a novel peptide that inhibits the pro-inflammatory effects of overactive MARCKS protein. It is a ten-amino acid peptide that inhibits the phosphorylation of the MARCKS protein (myristoylated alanine rich protein kinase C substrate), which is a substrate for protein kinase C. BIO-11006 is in Phase II clinical studies for the treatment of Adult respiratory distress syndrome, chronic obstructive pulmonary disease, and Non-small cell lung cancer.
MultiStem is an “”off-the-shelf”” stem cell product candidate, manufactured from Multipotent Adult Progenitor Cells. These cells are distinct from mesenchymal stem cells (MSCs) and other cell types. The drug is in Phase III clinical studies for the treatment of ischemic stroke and Acute Respiratory Distress Syndrome. The therapy has the equivalent of Fast Track status in Japan. In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the Acute Respiratory Distress Syndrome program.
Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for Acute Respiratory Distress Syndrome. The companies which have their Acute Respiratory Distress Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Athersys.
Find out more about the Acute Respiratory Distress Syndrome Pipeline Segmentation, Therapeutics Assessment, and Acute Respiratory Distress Syndrome Emerging Drugs @ Acute Respiratory Distress Syndrome Treatment Landscape
Scope of the Acute Respiratory Distress Syndrome Pipeline Report
Dive deep into rich insights for drugs for Acute Respiratory Distress Syndrome Pipeline Companies and Therapies, click here @ Acute Respiratory Distress Syndrome Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Acute Respiratory Distress Syndrome Mergers and acquisitions, Acute Respiratory Distress Syndrome Licensing Activities @ Acute Respiratory Distress Syndrome Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/